Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

Multimodality treatment provides modest survival benefits for patients with locally advanced (stage III) non-small-cell lung cancer (NSCLC). Nevertheless, preoperative immunotherapy has continuously been shown to be promising in treating resectable NSCLC.This phase 2 trial enrolled patients with AJC...

Full description

Saved in:
Bibliographic Details
Main Authors: Ze-Rui Zhao, Chao-Pin Yang, Si Chen, Hui Yu, Yong-Bin Lin, Yao-Bin Lin, Han Qi, Jie-Tian Jin, Shan-Shan Lian, Yi-Zhi Wang, Jin-Qi You, Wen-Yu Zhai, Hao Long
Format: article
Language:EN
Published: Taylor & Francis Group 2021
Subjects:
lung cancer
neoadjuvant
immunotherapy
chemotherapy
toripalimab
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/d071f34e1bff4d239614d466b1517629
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/d071f34e1bff4d239614d466b1517629

Similar Items